| pubmed-article:11417988 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11417988 | lifeskim:mentions | umls-concept:C1457887 | lld:lifeskim |
| pubmed-article:11417988 | lifeskim:mentions | umls-concept:C0024586 | lld:lifeskim |
| pubmed-article:11417988 | lifeskim:mentions | umls-concept:C2587213 | lld:lifeskim |
| pubmed-article:11417988 | lifeskim:mentions | umls-concept:C0203608 | lld:lifeskim |
| pubmed-article:11417988 | lifeskim:mentions | umls-concept:C0879568 | lld:lifeskim |
| pubmed-article:11417988 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:11417988 | pubmed:dateCreated | 2001-6-21 | lld:pubmed |
| pubmed-article:11417988 | pubmed:abstractText | The standard treatment used to control the symptoms of carcinoid syndrome (CS) involves subcutaneous injections of the somatostatin analogue octreotide. This is expensive (US $8000--16,000 per year), and treatment may be for many years. The aim of this study was to evaluate the efficacy and cost-effectiveness of our experience over the last 5 years with 1-131-labelled metaiodobenzylguanidine (MIBG) radionuclide therapy in the palliation of patients with CS. | lld:pubmed |
| pubmed-article:11417988 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11417988 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11417988 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11417988 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11417988 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11417988 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11417988 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11417988 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11417988 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11417988 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11417988 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11417988 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:11417988 | pubmed:issn | 0748-7983 | lld:pubmed |
| pubmed-article:11417988 | pubmed:author | pubmed-author:PostonG JGJ | lld:pubmed |
| pubmed-article:11417988 | pubmed:author | pubmed-author:ByrneCC | lld:pubmed |
| pubmed-article:11417988 | pubmed:author | pubmed-author:VoraJJ | lld:pubmed |
| pubmed-article:11417988 | pubmed:author | pubmed-author:VinjamuriSS | lld:pubmed |
| pubmed-article:11417988 | pubmed:author | pubmed-author:GhanehPP | lld:pubmed |
| pubmed-article:11417988 | pubmed:author | pubmed-author:PathiranaA... | lld:pubmed |
| pubmed-article:11417988 | pubmed:copyrightInfo | Copyright Harcourt Publishers Limited. | lld:pubmed |
| pubmed-article:11417988 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11417988 | pubmed:volume | 27 | lld:pubmed |
| pubmed-article:11417988 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11417988 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11417988 | pubmed:pagination | 404-8 | lld:pubmed |
| pubmed-article:11417988 | pubmed:dateRevised | 2009-7-23 | lld:pubmed |
| pubmed-article:11417988 | pubmed:meshHeading | pubmed-meshheading:11417988... | lld:pubmed |
| pubmed-article:11417988 | pubmed:meshHeading | pubmed-meshheading:11417988... | lld:pubmed |
| pubmed-article:11417988 | pubmed:meshHeading | pubmed-meshheading:11417988... | lld:pubmed |
| pubmed-article:11417988 | pubmed:meshHeading | pubmed-meshheading:11417988... | lld:pubmed |
| pubmed-article:11417988 | pubmed:meshHeading | pubmed-meshheading:11417988... | lld:pubmed |
| pubmed-article:11417988 | pubmed:meshHeading | pubmed-meshheading:11417988... | lld:pubmed |
| pubmed-article:11417988 | pubmed:meshHeading | pubmed-meshheading:11417988... | lld:pubmed |
| pubmed-article:11417988 | pubmed:meshHeading | pubmed-meshheading:11417988... | lld:pubmed |
| pubmed-article:11417988 | pubmed:meshHeading | pubmed-meshheading:11417988... | lld:pubmed |
| pubmed-article:11417988 | pubmed:meshHeading | pubmed-meshheading:11417988... | lld:pubmed |
| pubmed-article:11417988 | pubmed:meshHeading | pubmed-meshheading:11417988... | lld:pubmed |
| pubmed-article:11417988 | pubmed:meshHeading | pubmed-meshheading:11417988... | lld:pubmed |
| pubmed-article:11417988 | pubmed:meshHeading | pubmed-meshheading:11417988... | lld:pubmed |
| pubmed-article:11417988 | pubmed:meshHeading | pubmed-meshheading:11417988... | lld:pubmed |
| pubmed-article:11417988 | pubmed:meshHeading | pubmed-meshheading:11417988... | lld:pubmed |
| pubmed-article:11417988 | pubmed:meshHeading | pubmed-meshheading:11417988... | lld:pubmed |
| pubmed-article:11417988 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11417988 | pubmed:articleTitle | (131)I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome. | lld:pubmed |
| pubmed-article:11417988 | pubmed:affiliation | Department of Surgery, Royal Liverpool University Hospital, Prescot Street, Liverpool, L7 8XP, UK. | lld:pubmed |
| pubmed-article:11417988 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11417988 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11417988 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11417988 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11417988 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11417988 | lld:pubmed |
